However, further research is needed to determine if the variability in CD6 and CD318 expression is associated with patient clinical characteristics and whether the inverse correlation between the molecules is driven by reduced tumor-infiltrating lymphocytes or downregulation of CD6 through interaction with CD318 in tumor cells. This evidence concerns the gene CDCP1 and neoplasm.